



Scientist/Associate Scientist
Cancer Immunotherapy/Off-the-Shelf CAR-T Product Development
Job Code 294MM

Description

Fate's Cancer Immunotherapy group is seeking a motivated individual with expertise in cancer biology, immunology, cell biology or related field to join a multidisciplinary team dedicated to the discovery of novel off-the-shelf cellular therapeutics for the treatment of cancer and other disorders. The successful candidate will be responsible for the development and optimization of novel engineered lymphoid differentiation protocols, including the derivation of off-the-shelf CAR-T cells, from induced pluripotent stem cells (iPSC) as well as their functional assessment in various tumor models. The candidate will play a key role in research activities related to Memorial Sloan Kettering Cancer Center collaboration. The candidate must have experience with mammalian cell culture. The candidate will also play a key role in collaborating with top academic institutes to support discovery, manufacturing and clinical trials. This is a full-time position reporting to a Senior Scientist in Cancer Immunotherapy leading several off-the-shelf CART Product Development programs and is located at our New York Site in New York City, New York.

Primary Responsibilities Include:

- In depth in vitro analysis of iPSC-derived T and CAR-T cells utilizing flow cytometry, proliferation, cytokine secretion, serial stimulation, migration, cytotoxicity assays and other in-vitro assays
- Conduct and optimize various stages of iPSCs differentiation to lymphocyte lineage
- Investigate the role of unique genes and novel modalities in enhancing effector cell performance and persistence
- Engineering of various cell types, including lentiviral transduction of primary T cells
- Conduct/establish product release assays for iPSC derived and primary CAR-T cells
- Establishment and implementation of in vivo mouse models to assess in vivo cytotoxicity of iPSC-derived T and CAR-T cells against both liquid and solid tumors
- Detailed experimental design, record keeping, protocol writing and data interpretation
- Deliver/present results in a multidisciplinary team environment that includes collaborations with top research laboratories and institutes
- Coordination with manufacturing and process development teams in support of technology transfer to academic collaborators.

Requirements:

- PhD. in immunology, cancer biology or related field with 2 or more years of laboratory experience in academia, and/or pharmaceutical industry or M.S. degree in immunology, cancer biology or related field with 5 or more years of relevant industry experience
- Experience in cell culture techniques, flow cytometry, in-vitro immunoassays (activation, cytotoxic killing, cytokine release, migration)
- Experience with process and assay development to improve manufacturing of CAR-Ts
- Understanding and experience with iPSC and/or CAR-T cell technology is a plus



- Experience with manufacturing/cGMP guidelines is desirable
- Excellent communication (both written and oral), time management, record keeping and data analysis skills
- Positive attitude and willingness to learn and contribute in a goal-oriented team
- Experience using an EDMS system, particularly Veeva Regulatory Information Management (RIM) Suite
- Strong team orientation, with excellent written and oral communication skills

Working Conditions and Physical Requirements

- May require occasional evening and weekend work
- Full-time onsite work at Company's headquarters in San Diego
- May require occasional travel for training programs and meetings

The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.

For consideration send cover letter and resume to: careers@fatetherapeutics.com and reference Job Code 294MM.

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company's immuno-oncology pipeline is comprised of universal, off-the-shelf NK cell and T-cell product candidates that are mass produced using its industry-leading induced pluripotent stem cell (iPSC) product platform. In 2019, Fate Therapeutics initiated the first-ever clinical trial in the United States of an iPSC-derived cell product, and is developing this NK cell cancer immunotherapy, FT500, for the treatment of patients with advanced solid tumors and lymphomas that are resistant to checkpoint inhibitor therapy. The Company is also developing FT516, an engineered iPSC-derived NK cell product candidate incorporating a novel high-affinity, non-cleavable 158V CD16 Fc receptor for enhanced binding to monoclonal antibodies, and is advancing a highly-differentiated pipeline of iPSC-derived chimeric antigen receptor (CAR) NK cell and T-cell product candidates designed to simultaneously engage multiple tumor-associated antigens for the treatment of hematologic malignancies and solid tumors. The Company's immuno-regulatory pipeline includes ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of acute graft-versus-host disease (GvHD), and an iPSC-derived myeloid-derived suppressor cell (MDSC) immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.